Clinical trial
A Phase 1b/2 Study Evaluating the Safety and Preliminary Efficacy of OM-RCA-01, an Anti-FGFR1 Monoclonal Antibody, in Patients With Metastatic Cancers Expressing FGFR1.
NCT07292168 is registered in ClinicalTrials.gov with Kidney Cancer Research Bureau as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Study Evaluating the Safety and Preliminary Efficacy of OM-RCA-01, an Anti-FGFR1 Monoclonal Antibody, in Patients With Metastatic Cancers Expressing FGFR1.
- Lead sponsor
- Kidney Cancer Research Bureau
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- December 2, 2025
- Completion date
- January 1, 2027
- Enrollment
- 58 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer metastatic, head & neck cancer, non-small cell lung cancer metastatic, prostate cancer metastatic, renal cell carcinoma metastatic